These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24759231)

  • 1. Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility.
    Procaccia V; Nakayama H; Shimizu A; Klagsbrun M
    Biochem Biophys Res Commun; 2014 May; 448(2):134-8. PubMed ID: 24759231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.
    Shimizu A; Mammoto A; Italiano JE; Pravda E; Dudley AC; Ingber DE; Klagsbrun M
    J Biol Chem; 2008 Oct; 283(40):27230-8. PubMed ID: 18660502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis.
    Guttmann-Raviv N; Shraga-Heled N; Varshavsky A; Guimaraes-Sternberg C; Kessler O; Neufeld G
    J Biol Chem; 2007 Sep; 282(36):26294-305. PubMed ID: 17569671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gleevec target Abl important for normal immune activation of T cells.
    Cancer Biol Ther; 2004 Aug; 3(8):704. PubMed ID: 15751157
    [No Abstract]   [Full Text] [Related]  

  • 6. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
    Lin YL; Roux B
    J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RhoA-kinase coordinates F-actin organization and myosin II activity during semaphorin-3A-induced axon retraction.
    Gallo G
    J Cell Sci; 2006 Aug; 119(Pt 16):3413-23. PubMed ID: 16899819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration.
    Popow-Woźniak A; Woźniakowska A; Kaczmarek L; Malicka-Błaszkiewicz M; Nowak D
    Eur J Pharmacol; 2011 Sep; 667(1-3):66-73. PubMed ID: 21658383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semaphorin-induced cytoskeletal collapse and repulsion of endothelial cells.
    Bielenberg DR; Shimizu A; Klagsbrun M
    Methods Enzymol; 2008; 443():299-314. PubMed ID: 18772022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
    Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
    Frasca F; Vigneri P; Vella V; Vigneri R; Wang JY
    Oncogene; 2001 Jun; 20(29):3845-56. PubMed ID: 11439348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.
    Salah E; Ugochukwu E; Barr AJ; von Delft F; Knapp S; Elkins JM
    J Med Chem; 2011 Apr; 54(7):2359-67. PubMed ID: 21417343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
    Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate (Gleevec) induces human corpus cavernosum relaxation by inhibiting receptor tyrosine kinases (RTKs): identification of new RTK targets.
    Gur S; Sikka SC; Abdel-Mageed AB; Abd Elmageed ZY; Rezk B; Pankey E; Kadowitz PJ; Hellstrom WJ
    Urology; 2013 Sep; 82(3):745.e11-6. PubMed ID: 23856589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
    Gobin B; Moriceau G; Ory B; Charrier C; Brion R; Blanchard F; Redini F; Heymann D
    PLoS One; 2014; 9(3):e90795. PubMed ID: 24599309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaphorin 3A blocks the formation of pathologic choroidal neovascularization induced by transforming growth factor beta.
    Bai Y; Liang S; Yu W; Zhao M; Huang L; Zhao M; Li X
    Mol Vis; 2014; 20():1258-70. PubMed ID: 25352735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
    Kirschner KM; Baltensperger K
    Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between biomechanical alterations and migratory ability of semaphorin-3A-treated thymocytes.
    Lins MP; Silva ECO; Silva GR; Souza ST; Medeiros NC; Fonseca EJS; Smaniotto S
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):816-824. PubMed ID: 29305907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
    Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.